Adam Schechter Sells 8,705 Shares of Labcorp (NYSE:LH) Stock

Key Points

• Labcorp CEO Adam Schechter sold 8,705 shares on March 3 at an average price of $279.96 for about $2.44 million, cutting his ownership by 9.73% to 80,773 shares valued at roughly $22.6 million.
• Labcorp reported quarterly EPS of $4.07 (above the $3.95 estimate) with revenue of $3.52 billion (slightly below estimates) and set FY2026 guidance of 17.55–18.25 EPS versus analyst expectations of about 16.01 EPS.
• The company declared a quarterly dividend of $0.72 per share (annualized $2.88, ~1.0% yield), and analysts have raised price targets leaving a consensus "Moderate Buy" with an average target near $304.82.

Labcorp Holdings Inc. (NYSE:LH - Get Free Report) CEO Adam Schechter sold 8,705 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total value of $2,437,051.80. Following the completion of the transaction, the chief executive officer owned 80,773 shares of the company's stock, valued at $22,613,209.08. This represents a 9.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Labcorp Stock Down 0.8%

Labcorp stock opened at $280.85 on Thursday. Labcorp Holdings Inc. has a twelve month low of $209.38 and a twelve month high of $293.72. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60. The company has a 50 day moving average of $270.25 and a 200-day moving average of $270.26. The stock has a market capitalization of $23.14 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.93 and a beta of 1.01.

Labcorp (NYSE:LH - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping analysts' consensus estimates of $3.95 by $0.12. The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The company's revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, equities research analysts anticipate that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. Labcorp's dividend payout ratio is 27.53%.

Analyst Ratings Changes

A number of brokerages have recently commented on LH. Piper Sandler boosted their price objective on shares of Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. boosted their price target on shares of Labcorp from $319.00 to $330.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Robert W. Baird increased their price objective on shares of Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 18th. Wall Street Zen raised Labcorp from a "hold" rating to a "buy" rating in a research report on Friday, January 23rd. Finally, Morgan Stanley reissued an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $304.82.

Institutional Investors Weigh In On Labcorp

A number of large investors have recently bought and sold shares of the company. Caldwell Trust Co acquired a new stake in shares of Labcorp during the 2nd quarter worth approximately $25,000. Financial Gravity Companies Inc. bought a new stake in Labcorp during the second quarter worth $26,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Labcorp in the 4th quarter valued at $26,000. Hilton Head Capital Partners LLC bought a new position in shares of Labcorp in the 4th quarter valued at $27,000. Finally, JPL Wealth Management LLC bought a new stake in shares of Labcorp during the 3rd quarter worth $28,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.